Quad's vincristine sulfate
Executive SummaryPar Pharmaceutical's subsidiary received FDA approval for the oncolytic agent in 1 mg/ml injectable in 1, 2, and 5 mg vials. Quad said it will launch the product, the first generic form of Lilly's Oncovin, the week of May 13. Par said the firm also received approval for a preservative-free form of vincristine.
You may also be interested in...
As part of its response to the coronavirus outbreak, the European association representing generic and biosimilar drug companies, Medicines for Europe, has set out a series of policy recommendations that it says could help to mitigate the possible risks to medicines supply.
Podcast: Living In China's Coronavirus Lockdown, Novartis and England's 'Public Health' Alliance; Biogen's Moment of Truth Approaches
Japan bioventure BioComo was set up around 10 years ago and has since been honing its technology platform. It is now preparing to move into the clinic with a novel vector for immuno-oncology and to raise new funds to support pipeline development.